David Nixon, MD
Hematology & Oncology · Jonesboro, ARNPI 1700846045
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,380 of the $1,718 with a category attached, or 80.3%. It is spread thinly across 29 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in AR, where the typical reported total is $4,667.
Across 83 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$170
- Pfizer$153
- AbbVie$150
- Johnson & Johnson$115
- Seagen Inc.$100
- Sanofi-aventis U.S. LLC$100
- plus $930 from 23 others
Across 5 payments — averaging $1262.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Puma Biotechnology, Inc.$6K
- AbbVie$411
What the payments were for
- Food & beverage$1,38080%
- Education$33920%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $170 |
| Pfizer | 8 | $153 |
| AbbVie | 8 | $150 |
| Johnson & Johnson | 6 | $115 |
| Seagen Inc. | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Sumitomo Pharma America, Inc. | 4 | $99 |
| Daiichi Sankyo Inc. | 4 | $95 |
| Incyte Corporation | 1 | $91 |
| AstraZeneca(2 entities) | 6 | $86 |
| Gilead | 5 | $78 |
| Beigene USA, Inc. | 3 | $55 |
| GSK | 3 | $49 |
| Astellas Pharma US Inc | 3 | $47 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $36 |
| Exelixis Inc. | 2 | $34 |
| Puma Biotechnology, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $33 |
| Ipsen Biopharmaceuticals, Inc | 2 | $29 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Tesaro, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Global Blood Therapeutics, Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| G1 Therapeutics, Inc. | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Sanofi | 1 | $12 |
| Taiho Oncology, Inc. | 1 | $12 |
How this compares
$1,718 in reported general payments places this provider in the 35th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 11 | $153,451 |
| Abiraterone Acetate | 13 | $61,333 |
| Sunitinib Malate | 12 | $55,257 |
| EliquisApixaban | 18 | $17,687 |
| SavaysaEdoxaban Tosylate | 12 | $4,990 |
| Hydroxyurea | 62 | $1,413 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $836 |
| Celecoxib | 12 | $180 |
| Gabapentin | 20 | $172 |
| Dexamethasone | 11 | $149 |
| Levothyroxine Sodium | 11 | $66 |
| Clonazepam | 11 | $66 |
| Prednisone | 23 | $65 |
| Allopurinol | 13 | $32 |
| Hydrochlorothiazide | 16 | $2 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $55 | $153,45111 claims |
| PfizerEliquis | $153 | $17,68718 claims |
| Daiichi Sankyo Inc.Savaysa | $95 | $4,99012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Jonesboro
- Mazen KhalilJonesboro$18K
- Carroll ScrogginJonesboro$7K
- Scott DorrohJonesboro$6K
- Eric SchaeferFayetteville$466K
- Frits van RheeLittle Rock$218K
- Isam Abdel-KarimFort Smith$199K
- Appalanaidu SasapuLittle Rock$63K
- Stephan RosenfeldFayetteville$61K
- Stephen DiversHot Springs$55K
- Humdum DurraniFort Smith$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.